Cell2Cure ApS
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://cell2cure.com
ASCs in Recently Diagnosed Non-ischemic Heart Failure
Phase 2
Not yet recruiting
- Conditions
- Non-Ischemic Heart FailureReduced Ejection Fraction Heart Failure
- Interventions
- Drug: Allogeneic adipose tissue-derived mesenchymal stem cellsOther: Cryostor CS10
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Cell2Cure ApS
- Target Recruit Count
- 90
- Registration Number
- NCT06840275
- Locations
- 🇩🇰
Cardiology Stem Cell Centre, Department of Cardiology, The Heart Centre, Rigshospitalet, University of Copenhagen, Denmark, København, Denmark
ASC - Autism Study
Phase 1
Recruiting
- Conditions
- Leaky Gut SyndromeGastrointestinal DysfunctionMesenchymal Stromal CellsAutism Spectrum DisorderInflammatory Bowel Diseases
- Interventions
- Drug: Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Cell2Cure ApS
- Target Recruit Count
- 10
- Registration Number
- NCT05602116
- Locations
- 🇩🇰
Department of Child and Adolescent Psychiatry, Psychiatry Clinic South, Aalborg University Hospital, Denmark, Aalborg, Denmark
Effect of Mesenchymal Stem Cells on Healing of Foot Ulcers in Diabetes Patients.
Phase 1
Recruiting
- Conditions
- Diabetic Foot UlcerMesenchymal Stromal Cells
- Interventions
- Drug: Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Cell2Cure ApS
- Target Recruit Count
- 30
- Registration Number
- NCT05595681
- Locations
- 🇩🇰
Copenhagen Diabetes Foot Center (CODIF), Copenhagen, Denmark
© Copyright 2025. All Rights Reserved by MedPath